Baricitinib

Specifications

1187594-09-7CAS Number

691-421-4EC Number

2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrileIUPAC Name

C16H17N7O2SChemical Formula

371.4 g/molMolecular Weight

Baricitinib; 1187594-09-7; olumiant; LY3009104; INCB028050; INCB 028050; INCB-028050; 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile; LY 3009104; LY-3009104; ISP4442I3Y; CHEBI:95341; DTXSID30152228; 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-; baricitinibum; (1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile; {1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile; 2-(3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile; RefChem:6387; JAK inhibitors: baricitinib; DTXCID5074719; L04AA37; 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile; Baricitinib [USAN:INN]; 2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile; UNII-ISP4442I3Y; MFCD21608464; Baricitinib (INCB028050); 2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE; Baricitinib (phosphate); Baricitinib (LY3009104); LY3009104 (phosphate);INCB028050 (phosphate); 3JW; Baricitinib [USAN]; C16H17N7O2S; Baricitinib (LY3009104, INCB028050); INCB 28050; Olumiant (TN); Baricitinib (Standard); BARICITINIB [MI]; BARICITINIB [INN]; BARICITINIB [JAN]; BARICITINIB [WHO-DD]; MLS006011247; SCHEMBL871150; Baricitinib (JAN/USAN/INN); BARICITINIB [EMA EPAR]; GTPL7792; orb1305415; Baricitinib - Bio-X trade mark; CHEMBL2105759; SCHEMBL27246146; SCHEMBL28628968; SCHEMBL29349824; BARICITINIB [ORANGE BOOK]; EX-A413; XUZMWHLSFXCVMG-UHFFFAOYSA-N; GLXC-90043; HMS3651L17; HMS3672M15; HMS3747G21; HMS5081F19; SMSSF-0444066; SBR00076; BDBM50021656; EBC-11468; HY-15315R; NSC799357; s2851; AKOS022186127; AKOS025401933; CCG-268312; CS-0724; DB11817; DS-7641; FE30357; NSC-799357; PB27275; SB10845; SDCCGSBI-0654448.P001; NCGC00345839-01; NCGC00345839-12; NCGC00345839-14; NCGC00345839-16; 2-[1-(ethanesulfonyl)-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile; AC-27404; BB184033; DA-50940; HY-15315; SMR004703006; NS00072974; SW220096-1; Baricitinib (INCB28050, LY3009104)?; D10308; B022691; EN300-24435973; F468368; Q4860707; BRD-K53581288-001-02-9; Z2724205326; (1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile; {1-(Ethanesulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrileSynonyms